Polarean Imaging: new milestones and upcoming goals

Proactive - Interviews for investors

Polarean Imaging PLC CEO Christopher von Jako takes Proactive's Stephen Gunnion through the company's recent advancements and future plans. Von Jako shared insights on the oversubscribed financing closed in June, highlighting the support from strategic investors, including NUKEM Isotopes and Bracco. The funds are being allocated to expand the commercial sales team and promote the adoption of Polarean's pulmonary functional Xenon MRI technology. He also discussed the recent upgrades at the University of Virginia Health Hospital and the University of Kansas Medical Center, moving from research to clinical-grade polarizers. This follows similar upgrades at Cincinnati Children's Hospital and the University of Alabama, Birmingham. These upgrades are expected to drive wider adoption of Polarean's technology. Additionally, von Jako announced the submission of an NDA supplement to the FDA to lower the age for XENOVIEW administration to six years old. This milestone could significantly expand the US market, particularly in pediatric pulmonary care, as Polarean's technology avoids ionizing radiation. Looking ahead, Polarean remains focused on executing its five-pillar strategy for 2024, with continued growth and expansion of the commercial team to meet set targets. Visit Proactive's YouTube channel for more videos, and don't forget to like, subscribe, and enable notifications for future content. #PolareanImaging #MedicalTechnology #XenonMRI #PediatricCare #FDAApproval #HealthcareInnovation #ChristopherVonJako #Investors #PulmonaryHealth #MedicalResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews